10-Q: American Well Corporation Reports Second Quarter 2024 Results, Revenue Flat Amidst Re-platforming Efforts

American Well Corporation's Q2 2024 results show flat revenue year-over-year as the company continues its platform transition.

Summary

• American Well Corporation reported a net loss of $50.6 million for the second quarter of 2024, compared to a net loss of $93.5 million for the same period in 2023.
• Revenue remained relatively flat at $62.8 million in Q2 2024, compared to $62.4 million in Q2 2023.
• The company's platform subscription revenue decreased slightly to $27.5 million, while visit revenue increased to $28.7 million.
• For the first six months of 2024, the company's net loss was $124 million, compared to a net loss of $492 million for the same period in 2023.
• The company's total visits for the six months ended June 30, 2024, were approximately 3.2 million, consistent with the same period in 2023.
• The company is undergoing a re-platforming effort to its Amwell Converge platform, which has impacted revenue timing and customer churn.
• As of June 30, 2024, 69% of visits were provided on the Amwell Converge platform.
• The company's cash and cash equivalents decreased to $276.9 million as of June 30, 2024, from $372 million at the end of 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company shows improvement in net loss and is making progress with its platform transition, the flat revenue growth, cash burn, and ongoing operating losses are concerning. The company's future outlook is cautiously optimistic, but significant challenges remain.

Positives

• The net loss significantly improved year-over-year, decreasing from $93.5 million in Q2 2023 to $50.6 million in Q2 2024.
• The company maintained a consistent level of virtual care visits at approximately 3.2 million in the first six months of both 2023 and 2024.
• The company is making progress in transitioning clients to the Amwell Converge platform, with 69% of visits now on the new platform.
• The company is focused on delivering solutions to government clients, which is expected to drive future revenue growth.
• The company has a high patient and provider satisfaction rating of over 90% on the Amwell Converge platform.

Negatives

• Revenue remained flat year-over-year, indicating a lack of growth in the second quarter of 2024.
• Platform subscription revenue decreased slightly, suggesting some customer churn during the re-platforming process.
• The company's cash and cash equivalents decreased by approximately $95 million in the first six months of 2024.
• The company continues to experience operating losses, with a loss from operations of $127.4 million for the first six months of 2024.
• The re-platforming effort has impacted revenue timing and customer churn.

Risks

• The company faces risks related to weak growth and increased volatility in the digital care market.
• The company has a history of losses and may not achieve profitability.
• The company may face challenges in adapting to rapid technological changes.
• The company relies on a limited number of significant clients, and losing their business could negatively impact results.
• Increased competition from existing and potential new participants in the healthcare industry poses a risk.
• Changes in healthcare laws and regulations could affect the company's ability to operate.
• The company is subject to risks related to compliance with privacy regulations and potential cybersecurity breaches.
• Slower than expected growth in patient adoption of digital care could impact the company's performance.
• The company's ability to grow its base of affiliated and non-affiliated providers is crucial to meet patient demand.
• The company's relationship with the Defense Health Agency is subject to renewal and comparable financial terms.

Future Outlook

The company expects to continue investments in its government sector customers and the development of its government product, which it believes will drive revenue growth in the coming years. The company also expects to continue the migration of its remaining health plan and health system clients onto the Amwell Converge platform. The company believes that its existing cash and cash equivalents will be sufficient to meet its working capital and capital expenditure needs for at least the next 12 months.

Management Comments

• A major strategic focus for us in 2024 is the delivery of solutions to our government clients as well as our existing commercial clients.
• We are focused on the transformational steps necessary to re-accelerate growth during this period of transition.
• We also continue to focus on the migration of our remaining health plan and health system clients onto the Amwell Converge platform.

Industry Context

The company operates in the rapidly evolving digital healthcare market, facing competition from both established players and new entrants. The shift towards hybrid care models and the increasing adoption of telehealth services are key trends influencing the company's business. The company's re-platforming efforts and focus on government clients reflect its strategy to adapt to these trends and maintain a competitive edge.

Comparison to Industry Standards

• While specific competitor data is not provided in the document, the company's flat revenue growth contrasts with the broader trend of growth in the telehealth industry, suggesting potential challenges in market share capture.
• The company's focus on migrating clients to a new platform is similar to other technology companies undergoing significant upgrades, but the impact on customer churn and revenue timing is a key concern.
• The company's adjusted EBITDA loss of $34.9 million in Q2 2024, while improved year-over-year, indicates ongoing challenges in achieving profitability, which is a common issue for many growth-stage technology companies.
• The company's cash burn rate, with a decrease of approximately $95 million in cash and cash equivalents in the first six months of 2024, is a significant concern and needs to be monitored closely against industry benchmarks.
• The company's 3.2 million visits in the first six months of 2024 is a key metric, but its significance needs to be evaluated against the performance of other telehealth providers and the overall market growth.

Management Changes

Related Party Transactions

• The company has related-party transactions with Cleveland Clinic and CCAW, JV LLC, a joint venture with Cleveland Clinic.

Stakeholder Impact

• Shareholders may be concerned about the flat revenue growth and ongoing operating losses.
• Employees may be affected by the company's cost-cutting measures and restructuring efforts.
• Customers may experience some disruption during the platform transition.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will continue to focus on migrating clients to the Amwell Converge platform.
• The company will continue to invest in its government sector customers and the development of its government product.
• The company will continue to monitor its cash burn rate and explore options for additional financing if needed.

Key Dates

Keywords

telehealth, digital health, virtual care, platform subscription, healthcare technology, Amwell Converge, enterprise software, health systems, health plans, government healthcare